A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids

Trial Profile

A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Vilaprisan (Primary) ; Ulipristal
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms ASTEROID 2
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 03 Jul 2017 According to a Bayer media release, first results from this trial will be presented at an upcoming scientific congress.
    • 21 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 24 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top